JOUNCE THERAPEUTICS INC (JNCE)       0.7257  -0.06 (-7.54%)

0.7257  -0.06 (-7.54%)

US4811161011 - Common Stock - Premarket: 0.77 +0.04 (+6.1%)

Buy % Consensus

80
Analysts have set a mean price target of 6.32. This target is 771.43% above the current price.
JNCE was analyzed by 13 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about JNCE.
In the previous month the buy percentage consensus was at a similar level.
JNCE was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target

Price Low Median Mean High 0.733.036.126.3211.55 - 317.53% 743.32% 771.43% 1,491.57%

Up and Down Grades

Date Firm Action Rating
2022-11-11 Raymond James Downgrade Strong Buy -> Outperform
2022-08-31 Raymond James Maintains Strong Buy
2022-08-05 HC Wainwright & Co. Maintains Buy
2022-05-23 Piper Sandler Maintains Overweight
2022-05-11 Baird Downgrade Outperform -> Neutral
2022-05-06 Raymond James Upgrade Outperform -> Strong Buy
2022-02-04 Cowen & Co. Upgrade Market Perform -> Outperform
2021-11-05 Raymond James Maintains Outperform
2021-09-14 Raymond James Upgrade Market Perform -> Outperform
2021-03-15 Piper Sandler Initiate Overweight

Analyst Ratings Stock Screener Links

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA